Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Observational · No treatment assigned · 1 site · Peking University First Hospital
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflamatory Bowel Disease. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Patients who are clinically diagnosed with IBD in our hospital
- Disease activity is in the active stage
- Receiving biologics after diagnosis
Plus 1 more requirement(s). There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 200 participants are expected to take part.
- Start date: 2025-08-15.
- Main results expected around 2026-07-01 (estimate from the record).
- 1 study site listed (1 marked recruiting) in China.
Main thing being measured
- disease activity (up to 8 weeks)
In the researchers’ words
Inflammatory bowel disease (IBD) is a group of chronic progressive gastrointestinal diseases that can recur throughout life and for which there is no cure. Biologics, the first line of treatment, are not only expensive, but also 30-50% of patients lack response to this type of drug therapy.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflamatory Bowel Disease |
| Lead sponsor | Peking University First Hospital |
| Enrollment | 200 (estimated) |
| Start date | 2025-08-15 |
| Primary completion (est.) | 2026-07-01 |
| First posted | 2025-09-18 |
| Last updated | 2025-09-18 |
| Official title | Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease |
| ClinicalTrials.gov ID | NCT07181525 |
Interventions
- anti-cytokine antibodies (Drug)
Different kinds of biologics used to treat inflammatory bowel disease (including anti-cytokine antibodies) - anti-integrin antibodies (Drug)
Different kinds of biologics used to treat inflammatory bowel disease (including anti-integrin antibodies)
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients who are clinically diagnosed with IBD in our hospital * Disease activity is in the active stage * Receiving biologics after diagnosis * Have relevant data on clinical evaluation results after receiving biologics treatment Exclusion Criteria: * IBD patients who have not been treated with biologics after diagnosis * Patients diagnosed with IBD but also with other autoimmune diseases that require biologics to be treated * Patients with hematological diseases and other systemic chronic inflammatory diseases involving the intestine Patients with serious complications including malignant tumors and gastrointestinal perforation.
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital | Beijing | China | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.